Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €31.68B | 33.9x | 0.09 | €514.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €28.59B | 28.6x | -2.67 | €166.75 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €23.73B | -30.3x | 0.04 | €96.60 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific SE | Vienna | Healthcare | Biotechnology & Medical Research | €12.83B | 33.2x | 1.63 | €66.94 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €12.09B | 12x | 0.04 | €196.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €9.60B | 118.4x | -1.62 | €44.35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.88B | -6.5x | 0.03 | €28.08 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.36B | -6.5x | 0.05 | €7.47 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.05B | 5.8x | 0.04 | €4.69 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Vienna | Healthcare | Biotechnology & Medical Research | €981.79M | 2.3x | 0.01 | €5.90 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Valneva | Vienna | Healthcare | Biotechnology & Medical Research | €563.59M | -6.2x | 0.03 | €3.40 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vivoryon Therapeutics NV | Vienna | Healthcare | Biotechnology & Medical Research | €36.99M | -1.8x | -0.06 | €1.42 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medigene | Vienna | Healthcare | Biotechnology & Medical Research | €1.77M | -1.5x | €0.13 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |